RecruitingNCT06754345
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
Sponsor
The First Affiliated Hospital of Xiamen University
Enrollment
100 participants
Start Date
May 30, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) for the evaluation of PD-L1 expression in primary and/or metastatic tumors, compared with histopathological results.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with pd-l1 and tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 90 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06754345
Related Trials
68Ga-FAPI PET/CT in Patients With Various Types of Cancer
NCT044993651 location
Decoupling Immunotherapy Toxicity and Cancer Response
NCT073827521 location
SBRT-LATTICE-PATHY
NCT076452611 location
A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma
NCT074657961 location
A Study of Live Tumor Fragments of Surgical Resections
NCT070008641 location